Physician profile
Eric Lee Glines
NPI 1568630127
$4,819.77
in general payments reported to CMS, 2019-2025
27 companies · $559 in 2025
The $559 reported for 2025 was more than what 75% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,107 · 2022: $1,165 · 2023: $1,109 · 2024: $880 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,548.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,547.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,219.18 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $542.76 | 2021-2025 | Lifevest |
| Pfizer INC. | $438.69 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $422.92 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $316.84 | 2021-2025 | Camzyos, Eliquis |
| Inari Medical, INC. | $303.24 | 2022-2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $269.72 | 2021-2024 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $215.09 | 2021-2025 | Brilinta, Farxiga |
| Boston Scientific Corporation | $200.76 | 2021-2025 | Watchman Flx |
| Abiomed | $148.23 | 2022-2025 | |
| Atricure, INC. | $112.27 | 2021 | |
| Merck Sharp & Dohme LLC | $90.14 | 2024-2025 | Verquvo, Keytruda |
| Daiichi Sankyo INC. | $84.61 | 2022-2023 | Injectafer |
| Amgen INC. | $83.17 | 2021-2024 | Repatha |
| Alnylam Pharmaceuticals INC. | $73.71 | 2021-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $51.78 | 2022-2025 | Aveir |
| Cvrx, INC. | $47.41 | 2023 | Barostim Neo System |
| Medtronic, INC. | $37.41 | 2024 | Endurant Iis |
| Actelion Pharmaceuticals US, INC. | $33.63 | 2021 | |
| Lemaitre Vascular, INC. | $23.88 | 2024 | Tyke, Patch, Pledget and Intracardiac |
| Endologix LLC | $16.64 | 2024 | Alto Abdominal Stent Graft System |
| Inspire Medical Systems, INC. | $15.73 | 2025 | Inspire |
| Sanofi-Aventis U.S. LLC | $15.57 | 2023 | |
| Getinge USA Sales, LLC | $15.38 | 2021 | |
| Cardiva Medical, INC. | $14.68 | 2022 | |
| Amarin Pharma, INC. | $14.62 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Glines listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.